News on CV Therapeutics from BioPortfolio.com http://www.BioPortfolio.com Consolidated CV Therapeutics news from BioPortfolio.com Wed, 10 Feb 2010 06:57:41 GMT en Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Studyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039880&HITNO=0&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039880&THISHREF=http://c.moreover.com/click/here.pl%3fz2538447157%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039880&HITNO=0&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039880&THISHREF=http://c.moreover.com/click/here.pl%3fz2538447157%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmaceuticalProcessing: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 ...http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039357&HITNO=1&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039357&THISHREF=http://c.moreover.com/click/here.pl%3fz2538057086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039357&HITNO=1&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039357&THISHREF=http://c.moreover.com/click/here.pl%3fz2538057086%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPipelineReview: Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Periodhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039293&HITNO=2&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039293&THISHREF=http://c.moreover.com/click/here.pl%3fz2537999804%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039293&HITNO=2&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039293&THISHREF=http://c.moreover.com/click/here.pl%3fz2537999804%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTransplantation: Genetic Testing Heads to the Pharmacyhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039904&HITNO=3&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039904&THISHREF=http://c.moreover.com/click/here.pl%3fz2538459956%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039904&HITNO=3&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039904&THISHREF=http://c.moreover.com/click/here.pl%3fz2538459956%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTechnology Review: Patterns of Chronic Injury in Pediatric Renal Allograftshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039292&HITNO=4&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039292&THISHREF=http://c.moreover.com/click/here.pl%3fz2537999740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039292&HITNO=4&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039292&THISHREF=http://c.moreover.com/click/here.pl%3fz2537999740%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTransplantation: IPO Hopeful Anthera Gets SPA on Pivotal CV Outcomes Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032884&HITNO=5&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032884&THISHREF=http://c.moreover.com/click/here.pl%3fz2534847844%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032884&HITNO=5&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032884&THISHREF=http://c.moreover.com/click/here.pl%3fz2534847844%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study;http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=6&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034853&HITNO=6&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034853&THISHREF=http://c.moreover.com/click/here.pl%3fz2536014104%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHealthcare Sales & Marketing Network: Varicose veins, factors for CV must be evaluated before any surgical procedurehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032702&HITNO=7&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032702&THISHREF=http://c.moreover.com/click/here.pl%3fz2534774303%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032702&HITNO=7&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032702&THISHREF=http://c.moreover.com/click/here.pl%3fz2534774303%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comModern Medicine: CVS settles Indiana complaint over 2 pharmacistshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038356&HITNO=8&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038356&THISHREF=http://c.moreover.com/click/here.pl%3fz2537579347%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038356&HITNO=8&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038356&THISHREF=http://c.moreover.com/click/here.pl%3fz2537579347%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWashington Post: (CVS) SqueezeTrigger Price is $32.942. There is $616,280,045.00 That Short Sellers Still Need To Coverhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033475&HITNO=9&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033475&THISHREF=http://c.moreover.com/click/here.pl%3fz2535222173%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033475&HITNO=9&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033475&THISHREF=http://c.moreover.com/click/here.pl%3fz2535222173%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: FTC probing CVS Caremark's prescription drug practiceshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032701&HITNO=10&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032701&THISHREF=http://c.moreover.com/click/here.pl%3fz2534774329%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032701&HITNO=10&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032701&THISHREF=http://c.moreover.com/click/here.pl%3fz2534774329%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comWashington Post: CVS profit rises in 4th quarter as revenue from Caremark pharmacy benefits unit increaseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034340&HITNO=11&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034340&THISHREF=http://c.moreover.com/click/here.pl%3fz2535721042%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4034340&HITNO=11&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4034340&THISHREF=http://c.moreover.com/click/here.pl%3fz2535721042%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Chinoin Pharmaceutical Products, S.A DE C.V-Company Report - new market report releasedhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033736&HITNO=12&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033736&THISHREF=http://c.moreover.com/click/here.pl%3fz2535368806%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4033736&HITNO=12&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4033736&THISHREF=http://c.moreover.com/click/here.pl%3fz2535368806%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPR inside: CVS Caremark 4Q profit grows 11 percenthttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032351&HITNO=13&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032351&THISHREF=http://c.moreover.com/click/here.pl%3fz2534616748%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4032351&HITNO=13&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4032351&THISHREF=http://c.moreover.com/click/here.pl%3fz2534616748%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Put trading soars on pharmaceutical concernhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037255&HITNO=14&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037255&THISHREF=http://c.moreover.com/click/here.pl%3fz2536998754%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4037255&HITNO=14&MSIZE=629&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=CV%20Therapeutics&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4037255&THISHREF=http://c.moreover.com/click/here.pl%3fz2536998754%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comSchaeffers Research: